ScreenerHero

STX Shield Therapeutics plc

LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · shieldtherapeutics.com
5.950GBp0.00%Mkt Cap: 69.47M $P/E: —

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Fera…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$57.06BUSD
TEVA
Teva Pharmaceutical Industries Limited Ordinary Shares
$46.10BUSDP/E 65.9
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$38.70BUSDP/E 18.3
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
ZTS
Zoetis Inc. Class A Common Stock
$28.80BUSDP/E 11.4
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated Common Stock
$11.06BUSD
RDY
Dr. Reddy's Laboratories Ltd Common Stock
$10.20BUSDP/E 29.2
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc. Class A Common Stock
$6.77BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8
HeadlineSourceTime
Older
Shield Therapeutics (LSE:STX): What Does Its Commercial Update Mean for the CFO Handover?
Kalkine Media
Shield Therapeutics PLC Share Price - STX, RNS News, Articles, Quotes, & Charts (LON:STX)
Proactive financial news
Transcript : Shield Therapeutics plc - Special Call
marketscreener.com
STX: Full US control of ACCRUFER® boosts profitability and growth in the leading iron therapy market
TradingView
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Proactive financial news
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...

Proactive
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Proactive Investors
Shield Therapeutics to Take Over US Commercialization of ACCRUFeR
marketscreener.com
Shield Therapeutics takes full control of ferric maltol product in US
London South East
Shield Therapeutics takes full US control of ACCRUFeR
Investing.com
Shield Therapeutics takes full US control of ACCRUFeR By Investing.com
Investing.com Canada
Shield Therapeutics takes full US control of ACCRUFeR By Investing.com
Investing.com UK
REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
TradingView
Gateshead pharma firm Shield Therapeutics 'on track for full year profitability' - business-live.co.uk
Shield Therapeutics loss shrinks as milestone, royalty receipts grow
London South East
Shield Therapeutics jumps 11% as losses narrow and profitability target held
Proactive financial news
Shield Therapeutics jumps 11% as losses narrow and profitability target held

Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) rose 11% to 4.89p on Thursday after the pharmaceutical company reported sharply narrower half-year losses and reaffirmed its aim of reaching operating profitability in 2026. Peel Hunt reiterated its 'buy' rating and 15p price target,...

Proactive
Shield Therapeutics jumps 11% as losses narrow and profitability target held
Proactive Investors
Shield Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2026
marketscreener.com
Shield Therapeutics cuts H1 loss as ACCRUFeR growth drives revenue higher
Yahoo Finance UK
Shield Therapeutics (LSE:STX) Puts Pharmaceutical Execution Under the Lens as medicine commercialisation Leads Today's Debate
Kalkine Media
Shield Therapeutics Plc
RResearch Tree
Shield Therapeutics (LSE:STX) Puts Pharmaceutical Execution Under the Lens
Kalkine Media
Shield Therapeutics plc (SHIEF) Analyst insights, Price targets and Recommendations
Yahoo Finance Singapore
Loss-Making Shield Therapeutics plc (LON:STX) Expected To Breakeven In The Medium-Term
webull.com
Shield Therapeutics Plc Revenue Breakdown – LSE:STX
TradingView
Loss-Making Shield Therapeutics plc (LON:STX) Expected To Breakeven In The Medium-Term
simplywall.st
Shield Therapeutics signals it is on track for profitability - business-live.co.uk
Shield Therapeutics shares slip after interims, small-cap pharma says its still 'on-track'
Proactive Investors
Shield Therapeutics Increases First-Half Revenue and Strengthens Commercial Strategy
Yahoo Finance UK
Price to earnings forward of Shield Therapeutics Plc – LSE:STX
TradingView
STX Stock Price and Chart — LSE:STX
TradingView